Literature DB >> 11504463

The IGF/IGF-1 receptor signaling pathway as a potential target for cancer therapy.

Ingo Burtscher1, Gerhard Christofori.   

Abstract

Expression of insulin-like growth factors (IGFs) and their cognate receptor, the IGF-1 receptor, is frequently upregulated during the development of many types of cancer. Besides stimulating cell cycle progression and the transformation status of tumor cells, a wealth of recent experimental data suggests that IGF-mediated signaling exerts a central tumor-promoting function through the repression of tumor cell apoptosis. These functions are all conveyed by the IGF-1 receptor, thus making it an attractive target for therapeutic intervention. Notably, inhibition of IGF-mediated survival function appears to synergize with conventional chemotherapeutic ablation of tumor cells, raising the possibility of combinatorial cancer therapies with significantly reduced side-effects. Copyright 1999 Harcourt Publishers Ltd.

Entities:  

Year:  1999        PMID: 11504463     DOI: 10.1054/drup.1998.0061

Source DB:  PubMed          Journal:  Drug Resist Updat        ISSN: 1368-7646            Impact factor:   18.500


  3 in total

1.  Heterogeneity for IGF-II production maintained by public goods dynamics in neuroendocrine pancreatic cancer.

Authors:  Marco Archetti; Daniela A Ferraro; Gerhard Christofori
Journal:  Proc Natl Acad Sci U S A       Date:  2015-01-26       Impact factor: 11.205

2.  Type I insulin-like growth factor receptor over-expression induces proliferation and anti-apoptotic signaling in a three-dimensional culture model of breast epithelial cells.

Authors:  Gina M Yanochko; Walter Eckhart
Journal:  Breast Cancer Res       Date:  2006-04-03       Impact factor: 6.466

3.  Establishment of a novel human CIC-DUX4 sarcoma cell line, Kitra-SRS, with autocrine IGF-1R activation and metastatic potential to the lungs.

Authors:  Sho Nakai; Shutaro Yamada; Hidetatsu Outani; Takaaki Nakai; Naohiro Yasuda; Hirokazu Mae; Yoshinori Imura; Toru Wakamatsu; Hironari Tamiya; Takaaki Tanaka; Kenichiro Hamada; Akiyoshi Tani; Akira Myoui; Nobuhito Araki; Takafumi Ueda; Hideki Yoshikawa; Satoshi Takenaka; Norifumi Naka
Journal:  Sci Rep       Date:  2019-11-01       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.